In Memoriam: Rick Jobus, Feb. 6, 1958-June 19, 2022

In Memoriam: Rick Jobus, Feb. 6, 1958-June 19, 2022

Courtesy of Rick Jobus It is with deep sadness that we inform the ALS News Today community of the passing of our friend and treasured columnist, Rick Jobus, on June 19, 2022. Rick published the first installment of his column, “Notes From the ALS Front,”…

I Just Received a Diagnosis of ALS. What Now?

Sometimes the simplest things can help us the most. That’s what I learned in the months right after I received a diagnosis of ALS. Like most newly diagnosed ALS patients, I felt overwhelmed trying to find out what ALS was, not really wanting to know, and just wishing…

At-home Music Therapy Program May Help Bulbar-onset Patients

An at-home music therapy program aimed at improving speech, swallowing, and respiration in people with amyotrophic lateral sclerosis (ALS) was well-tolerated and feasible, according to a small pilot study. While the pilot study (NCT03604822) was not designed to test the program’s effectiveness, collected data suggest that the music…

FDA Grants Orphan Drug Status to TQS-168 for ALS Treatment

The U.S. Food and Drug Administration has granted orphan drug designation to Tranquis Therapeutics‘ experimental therapy TQS-168 for treating amyotrophic lateral sclerosis (ALS). Orphan drug status is given to experimental therapies with promise for treating rare diseases — those affecting fewer than 200,000 people in the U.S.

What Risks Are We Willing to Take?

“What if Todd had aspirated while you were on your spring break trip?” someone asked me. That’s the type of question I’ve asked myself many times over the last decade since my husband, Todd, was diagnosed with ALS. What risks are we willing to take to…

ILB Safe, Shows Potential to Slow ALS Progression in Small Phase 2 Trial

TikoMed reported that ILB, its investigational therapy to protect nerve cells in amyotrophic lateral sclerosis (ALS), was well-tolerated by patients, and led to improvements in mobility and disease severity while reducing spasticity scores in a small open-label clinical trial. “These early results from this ALS-study are exciting as ILB provided beneficial…